Dyne Therapeutics, Inc.
NASDAQ:DYNBiotechnology
+$0.38 today
- Market cap
- $2.97B
- Beta
- 1.08
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$2.74
Volume 2.93M
Average 1.71M
DYN Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Dyne Therapeutics, Inc.NASDAQ: DYN
Common Stock · Q2 FY2026 · quarter ended Jun 2026
Common stock rises 45.5% from a year ago
Common stock stood at $16K at the end of Q2 FY2026, up 45.5% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +38.7% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +45.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 16K USD
- Year-over-year change
- +60.0%
- 4-year CAGR
- +27.8%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16K | +60.0% |
| FY2024 | 2024-12-31 | 10K | +66.7% |
| FY2023 | 2023-12-31 | 6K | +0.0% |
| FY2022 | 2022-12-31 | 6K | +0.0% |
| FY2021 | 2021-12-31 | 6K | — |
Common Stock vs competitors
How DYN compares with its peers on the latest reported figures
- DYN's Jun 2026 common stock of $16K is the 7th highest of the 11 companies compared; the peer median is $69.83K.
- Its year-over-year change of +45.5% is the 3rd highest of 11, against a peer median of +23.1%.
- Common stock amounts to 0.0% of total assets for DYN, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.63B | +37.9% | +26.3% | 278.8% | |
| Sep 2026 | $166K | +3.1% | +4.7% | 0.0% | |
| Mar 2026 | $103K | +60.9% | +24.5% | 0.0% | |
| Mar 2026 | $98K | +27.3% | +58.1% | 0.0% | |
| Jun 2026 | $82K | +5.1% | +3.6% | 0.0% | |
| Mar 2026 | $57.67K | +26.2% | +31.5% | 0.0% | |
| Jun 2026 | $16K | +45.5% | +38.7% | 0.0% | |
| Mar 2026 | $11K | +10.0% | +6.9% | 0.0% | |
| Mar 2026 | $7K | +133.3% | +51.8% | 0.0% | |
| Mar 2026 | $6K | +20.0% | +7.7% | 0.0% | |
| Mar 2026 | $4K | +0.0% | +10.1% | 0.0% | |
| Peer median (excluding DYN) | $69.83K | +23.1% | +17.3% | 0.0% | |
Competitors are the stored peer set for DYN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 200.83M | 172.15M | 121.63M | 435.45M | 893.37M |
| Short-term Investments | 175.75M | 83.87M | 1.47M | 206.82M | 217.19M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 383K | 9.58M | 6.28M | 17.01M | 16.03M |
| Total Current Assets | 382.39M | 265.59M | 129.38M | 659.28M | 1.13B |
| Property, Plant & Equipment (Net) | 40.96M | 38.41M | 33.39M | 30.01M | 44.77M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.31M | 2.32M | 2.32M | 1.94M | 15.6M |
| Total Non-current Assets | 43.27M | 40.73M | 35.71M | 31.96M | 60.37M |
| Total Assets | 425.66M | 306.33M | 165.08M | 691.23M | 1.19B |
| Account Payables | 4.03M | 5.26M | 22.94M | 6.56M | 8.08M |
| Short-term Debt | 0 | 0 | 0 | 4.85M | 5M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 17.75M | 37.55M |
| Total Current Liabilities | 28.72M | 28.09M | 51.1M | 42.26M | 50.63M |
| Long-term Debt | 0 | 0 | 0 | 0 | 15.28M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 148.92M |
| Total Non-current Liabilities | 28.74M | 25.87M | 22.7M | 19.14M | 164.2M |
| Total Liabilities | 57.47M | 53.96M | 73.79M | 61.4M | 214.83M |
| Common Stock | 6K | 6K | 6K | 10K | 16K |
| Retained Earnings | (228.47M) | (396.57M) | (632.51M) | (949.93M) | (1.4B) |
| Accumulated OCI | (269K) | (571K) | 0 | 6K | 475K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 368.2M | 252.36M | 91.29M | 629.84M | 972.13M |
| Total Debt | 32.64M | 30.48M | 27.42M | 23.99M | 20.28M |
| Net Debt | (168.19M) | (141.66M) | (94.21M) | (411.46M) | (873.09M) |
Dyne Therapeutics, Inc.
NASDAQ:DYN
Intrinsic Alpha fair value
Locked
Current Price
$15.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.